Adaptive Design in Clinical Trials
Kaspar Rufibach, PhD, MSc
- Expert Statistical Scientist
- F. Hoffmann-La Roche AG, Methods, Collaboration, and Outreach Group (MCO), Switzerland
Kaspar Rufibach is a member of Roche's Methods, Collaboration, and Outreach group. He does methodological research, provides consulting to Roche statisticians and broader project teams, gives biostatistics trainings for statisticians and non-statisticians in- and externally, mentors students, and interacts with external partners in industry, regulators, and the academic community in various working groups and collaborations. He has co-founded and co-leads the European special interest group “Estimands in oncology” (sponsored by PSI and EFSPI) that currently has more than 35 members from 22 companies and several Health Authorities and works on various topics around estimands in oncology.
Weidong Zhang, PhD
- Vice President, Head of Biostatistics and Programming
- Jounce Therapeutics, United States
Dr. Weidong Zhang is currently the Vice President, Biostatistics and Programming at Jounce Therapeutics. He oversees biostatistics and programming to support end-to-end clinical development in immuno-oncology regarding study design, execution and medical affairs. Prior to Jounce, he was a Senior Director Biostatistics at Pfizer focusing on clinical development in inflammation & immunology and oncology. Dr. Zhang has 20 years of experience in all phases of clinical development including Phase 1/PoM, Early Signal of Efficacy (ESoE), Phase 2a/b, Phase 3 and low-interventional studies. He has extensive knowledge in biomarker enrichment design and adaptive design.